<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287259</url>
  </required_header>
  <id_info>
    <org_study_id>ChibaU</org_study_id>
    <nct_id>NCT02287259</nct_id>
  </id_info>
  <brief_title>Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)</brief_title>
  <official_title>A Randomized, Open Label Trial of Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tadashi Hasegawa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiba University</source>
  <brief_summary>
    <textblock>
      Determine the efficacy and tolerability of olanzapine for treatment of acute depression in
      patients with bipolar II or bipolar disorder NOS compared with lithium.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Montgomery- Ã…sberg Depression Rating(MADRS)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Young Mania Rating Scale(YMARS)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology Japanese version(QIDS-J)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State Trait Anxiety Inventory Form JYZ(STAI)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression for Bipolar Disorder(CGI-BP)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO start with 2.5mg daily once for 7days, since then flexible dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lithium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO start with 400mg daily twice for 7days, since then flexible dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <arm_group_label>Olanzapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lithium</intervention_name>
    <arm_group_label>Lithium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  major depressive episode in type2 bipolar disorder or bipolar disorder NOS.(MADRS more
             than 20 point)

          -  18years to 65years

          -  subjects who sign the informed consent document

        Exclusion Criteria:

          -  don't have Diabetes and abnormal metabolism of sugar

          -  not noticed as bipolar disorder

          -  have an organic brain disease

          -  pregnant or breastfeeding women

          -  don't have heart disease

          -  have actively suicidal thought(Suicidal ideation score of MADRS is 6)

          -  who are judged by the investigator to should be excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tadashi Hasegawa, Assistant professor</last_name>
    <phone>+81-43-222-7171</phone>
    <email>t0715.hasegawa@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tadashi Hasegawa</last_name>
      <email>t0715.hasegawa@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chiba University</investigator_affiliation>
    <investigator_full_name>Tadashi Hasegawa</investigator_full_name>
    <investigator_title>medical doctor(assistant professor)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

